ROIV
Roivant Sciences Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.6% ·
share flow +1.1% ·
net new positions 0.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 129 | +11 | 407.19M | $14.42B | +15 | −5 |
| Q1 2026 | 122 | +5 | 384.63M | $10.65B | +13 | −9 |
| Q4 2025 | 117 | +1 | 374.22M | $8.12B | +3 | −1 |
| Q3 2025 | 19 | +1 | 262.46M | $3.97B | +1 | −1 |
| Q2 2025 | 16 | +1 | 211.12M | $2.38B | +1 | — |
| Q1 2025 | 12 | +1 | 89.39M | $901.93M | +2 | −1 |
| Q4 2024 | 11 | -2 | 96.86M | $1.15B | — | −2 |
| Q3 2024 | 12 | -1 | 85.45M | $986.08M | +1 | −2 |
| Q2 2024 | 13 | — | 92.40M | $976.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 60.77M | +9.5% | $919.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | Morgan Stanley ✦ | 44.32M | — | $670.60M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 3 | BlackRock ✦ (passive) | 39.72M | -1.5% | $601.04M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 4 | The Vanguard Group ✦ (passive) | 38.80M | -1.3% | $587.12M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 5 | Viking Global Investors ✦ | 23.59M | -31.1% | $356.99M | 0.9% | ▼ Trim | 6 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 18.70M | -5.4% | $282.93M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 8.20M | +5.8% | $124.13M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Adage Capital Partners ✦ | 7.23M | +247.3% | $109.43M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 9 | Marshall Wace ✦ | 3.98M | +316.5% | $60.19M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | T. Rowe Price ✦ | 2.92M | +98.5% | $44.19M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Point72 Asset Management ✦ | 2.61M | -11.6% | $39.46M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 2.59M | +167.9% | $39.16M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | JPMorgan Chase ✦ | 2.46M | — | $37.20M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 14 | Goldman Sachs Group ✦ | 2.36M | — | $35.72M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 15 | Greenlight Capital (DME Capital) ✦ | 2.28M | -50.0% | $34.43M | 1.4% | ▼ Trim | 6 | SEC ↗ ×3 |
| 16 | Citadel Advisors ✦ | 968.20K | +96.7% | $14.65M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 548.06K | +554.9% | $8.29M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 18 | Gotham Asset Management ✦ | 330.48K | +744.1% | $5.00M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 70.37K | New | $1.06M | 0.0% | New | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $1.06M | 0.0% |
Exited
| Norges Bank | $6.95M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 436 holders, 528.48M shares, $14.35B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 900 sh · $32,913
Director · 16.85K sh · $607,948
Director · 600 sh · $24,228
Director · 400 sh · $16,180
Director · 4.34K sh · $172,002
Director · 4.71K sh · $186,972
Director · 20.00K sh · $798,000
Officer · 33.82K sh · $1.23M
Officer · 166.18K sh · $5.92M
Officer, Director · 144.76K sh · $5.28M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology